{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:47:39Z","timestamp":1757314059126,"version":"3.40.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.prro.2023.10.006","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T02:29:35Z","timestamp":1698892175000},"page":"e132-e140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiparametric Magnetic Resonance Imaging\u2013 Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-2851","authenticated-orcid":false,"given":"Nathaniel","family":"Camden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumyajit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudit","family":"Chowdhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Shors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Turian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7619-8912","authenticated-orcid":false,"given":"Dian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2023.10.006_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2023.10.006_bib0002","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.juro.2018.05.003","article-title":"Validation of prostate imaging reporting and data system version 2 for the detection of prostate cancer","volume":"200","author":"Hofbauer","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.10.006_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jmri.27546","article-title":"Performance of prostate imaging reporting and data system version 2.1 for diagnosis of prostate cancer: A systematic review and meta-analysis","volume":"54","author":"Park","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.prro.2023.10.006_bib0004","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: Results of the MD anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0005","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0007","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0008","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard versus dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijrobp.2017.07.021","article-title":"Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: A systematic review and meta-analysis along with therapeutic implications","volume":"99","author":"Datta","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0011","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2023.10.006_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low \u03b1\/\u03b2 ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0013","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0014","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0016","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0017","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0018","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijrobp.2020.07.2194","article-title":"An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high-and intermediate-risk prostate cancer","volume":"108","author":"Oh","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0019","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high-and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib26","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.23.00617","article-title":"Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate","volume":"41","author":"Roy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0020","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S1470-2045(08)70236-5","article-title":"Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the TROG 96.01 randomised controlled trial","volume":"9","author":"Denham","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0021","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ijrobp.2019.04.001","article-title":"Long-term benefits of dose-escalation in localized prostate cancer","volume":"104","author":"Spratt","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.10.006_bib0022","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1200\/JCO.2011.35.1924","article-title":"Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer","volume":"30","author":"Buyyounouski","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0023","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0024","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high-risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.10.006_bib0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023002849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023002849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T11:07:50Z","timestamp":1745665670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850023002849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1879850023002849"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2023.10.006","relation":{},"ISSN":["1879-8500"],"issn-type":[{"type":"print","value":"1879-8500"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiparametric Magnetic Resonance Imaging\u2013 Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2023.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}